Douglas Andreas Valverde

Dr. Douglas Andreas Valverde

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Crohn's & Colitis 360
Verified
Journal Article
Open access
JGJoão Augusto dos Reis Guerra
João Augusto dos Reis Guerra
DMDaniela Oliveira Magro
Daniela Oliveira Magro
CCClaudio Saddy Rodrigues Coy
Claudio Saddy Rodrigues Coy
DVDouglas Andreas Valverde
Douglas Andreas Valverde
EOEmilia Sousa de Oliveira
Emilia Sousa de Oliveira
PKPaulo Kotze
Paulo Kotze
Introduction: Biological therapy has transformed the natural course of inflammatory bowel disease, but there are still controversies regarding its potential to reduce surgical rates for Crohn’s disease (CD). This study, conducted with the support of the Brazilian National Healthcare System, aimed to analyze temporal trends in surgery and hospitalization rates among patients with CD and to correlate these data with the dispensing of azathioprine (AZA), infliximab (IFX), and adalimumab (ADA). Methodology: This retrospective observational study used data from the National Public Healthcare Department of Informatics through the TT Disease Explorer® platform from 2012 to 2022. Demographic data, medications used, and the prevalence of surgical procedures and hospitalizations associated with the International Classification of Diseases codes for CD were analyzed. Annual average percent changes (AAPCs) were calculated to assess temporal trends. Results: Between 2012 and 2022, there was a significant increase of 288.07% in the diagnoses of CD, rising from 27 551 to 106 917 cases. Concurrently, there was an increase in the absolute number of patients treated with AZA, IFX, and ADA, with increasing rates of 65.79%, 251.09%, and 242.48%, respectively. However, the proportion of patients receiving AZA per CD patients decreased by 57.28%, from 44.79% to 19.13% (AAPC = −7.94%, 95% CI, −8.05 to −7.83; P < .001). The use of IFX remained relatively stable, with a slight change from 13.82% to 12.50% (AAPC = 0.01%, 95% CI, −0.20 to 0.22; P = .935), while the use of ADA decreased by 11.75%, from 11.65% to 10.28% (AAPC = −1.74%, 95% CI, −2.48 to −1.82; P < .001). The absolute number of hospitalizations related to CD increased by 57.71%. Despite the rise in the number of cases and the greater availability of biological treatments, the proportion of hospitalized patients decreased by 59.29%, from 6.19% to 2.52% (AAPC = −7.04%, 95% CI, −7.42 to −6.66; P < .001). Similarly, the proportion of surgical procedures relative to the total number of cases decreased by 55.08%, from 1.09% to 0.49% (AAPC = −5.73%, 95% CI, −6.68 to −4.77; P < .001). Conclusions: Despite the cumulative increase in the prevalence of CD cases in the country and the absolute increase in the dispensing of biologics, the proportion of hospitalizations and surgical procedures among CD patients treated in the public health system in Brazil decreased.

1 November 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
FMFernando Sabino Marques Monteiro
Fernando Sabino Marques Monteiro
ASAndre Deeke Sasse
Andre Deeke Sasse
DADenizar Vianna Araujo
Denizar Vianna Araujo
RMRana R. McKay
Rana R. McKay
KTKarine Martins da Trindade
Karine Martins da Trindade
DHDaniel Herchenhorn
Daniel Herchenhorn
PURPOSE: The Brazilian Public Health System (BPHS) serves approximately 71,730 patients with prostate cancer (PC) every year for which androgen deprivation therapy (ADT) is the primary treatment for patients with advanced hormone-sensitive prostate cancer (aHSPC). Androgen receptor pathway inhibitors (ARPIs) are not accessible through the BPHS. Using the BPHS as a model, this study assesses the long-term economic effect of surgical versus medical castration in aHSPC treatment to strategize cost reduction and the incorporation of ARPI in developing countries. PATIENTS AND METHODS: Data of patients with aHSPC (ie, TxN1M0 ineligible for local treatment or TxNxM1) from the BPHS database were analyzed from January 1, 2011, to December 31, 2021, using the TECHTRIALS artificial intelligence platform. The main outcomes were quantitative and descriptive analyses as well as a cost analysis of surgical versus chemical castration. RESULTS: Of the 274,519 patients with aHSPC who received active treatment during the 11-year study period, 90% (n = 246,683) underwent chemical castration and 10% (n = 27,836) underwent bilateral subcapsular orchiectomy (BSO). The median duration of chemical castration was 28 months. The BPHS spent an estimated total of $665,552,091.40 US dollars (USD) on chemical castration and $5,939,348.47 USD on BSO, respectively. The cost per patient was $2,698 USD and $213.37 USD for chemical castration and BSO, respectively. Hypothetically, if all patients with aHSPC had undergone BSO, the total direct cost for the BPHS would have been $42,774,832.20 USD, saving $622,777,259.20 USD over 11 years, making it possible to offer low-dose abiraterone to 65% of aHSPC patients. CONCLUSION: On the basis of this extensive financial analysis from the world's largest public health system database, BSO appears to be a valuable alternative to chemical castration for treating aHSPC. In resource-limited environments, the cost savings from using BSO may allow access to drugs that will improve survival such as ARPIs.

26 May 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
IKIgor Age Kos
Igor Age Kos
FHFaissal Nemer Hajar
Faissal Nemer Hajar
GCGustavo Sarot Pereira da Cunha
Gustavo Sarot Pereira da Cunha
CCClaudia Corte
Claudia Corte
LFLuisa Augusto Furlan
Luisa Augusto Furlan
VAValderilio Azevedo
Valderilio Azevedo
Objective: Brazil was strongly affected by the COVID-19 pandemic. Its continental dimension and socio-demographic characteristics pose challenges to distribution and accessibility, making vaccination programs challenging. The objectives of the study were to describe the clinical and demographic characteristics of the general population vaccinated against COVID-19 by October 2021 and analyze the strategies implemented during the vaccination program. Study design and setting: A retrospective nationwide study that analyzed data from the OpenDataSUS platform of the Informatics Department of the Brazilian Ministry of Health (DataSUS), which contains information from all individuals in Brazil who have received at least one dose of any vaccine against COVID-19 approved by the National Health Agency (ANVISA) from 17 January to 3 October 2021. Results: Until 3 October, a total of 146,254,578 persons (68.6 per 100 inhabitants) received at least one dose of a vaccine in Brazil. The north and northeast regions had the lowest vaccination rates compared with the remaining regions (North: 56.8, Northeast: 62.0, South: 74.4, and Southeast: 73.2 per 100 inhabitants). Elderly individuals had the highest vaccination rates, particularly those above 70 years old. Heterologous dosing regimens were administered to 1,063,079 individuals (0.7% of those receiving the first dose). Conclusions: The COVID-19 vaccination program reached more than two-thirds of the population in Brazil by 9 months after its start, but the vaccination coverage was heterogeneous, reflecting the country’s geographic and socio-demographic characteristics. Establishing priority groups for vaccination was a main characteristic of the vaccination strategy. In addition, technology transfer agreements have played an important role in increasing vaccine accessibility.

1 March 2026 in JCO Global Oncology
Verified
Journal Article
Open access
FMFernando Sabino Marques Monteiro
Fernando Sabino Marques Monteiro
VSVinicius Carrera Souza
Vinicius Carrera Souza
KTKarine Martins da Trindade
Karine Martins da Trindade
ASAdriano Gonçalves e Silva
Adriano Gonçalves e Silva
AMAugusto Mota
Augusto Mota
ASAndrey Soares
Andrey Soares
PURPOSE: Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those treatments due to cost restriction and governmental approval. However, several non–survival-prolonging treatments (nspTx) continue to be offered to patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: We gathered retrospective data from patients with mCRPC treated under the Brazilian Public Health System (BPHS) from 2017 to 2023. Our analysis concentrated on assessing the treatment plans, the median duration of treatment (mDoT), and the costs associated with these plans. The main aim of this study was to clarify the overall expenses, timing, and types of therapies provided to patients with mCRPC. RESULTS: A cohort of 38,851 patients with mCRPC showed a mDoT of 20.5 months and total castration-resistant treatment costs of $333,200,939 US dollars (USD). Among them, 31,430 (81%) received survival-prolonging treatments (spTx), while 7,421 (19%) were given nspTx. The spTx group had a mDoT of 19.8 months, with total spending of $269,892,761 USD and an average cost per patient of $8,587.11 USD. The nspTx group's mDoT was 20.5 months, costing $63,308,180 USD in total and $8,530.95 USD per patient. Exploratory analysis indicated that funds spent on nonsurvival treatments for one patient could cover generic cabazitaxel (20 mg/m 2 once every 21 days, six cycles) for approximately two patients with mCRPC. CONCLUSION: This long-term analysis of the BPHS treatment of mCRPC shows substantial spending on spTx and nspTx. Although most patients received recommended spTx, 19% received nspTx at similar costs. Results indicate the need for reforms to prioritize evidence-based treatments in resource-limited settings.

1 May 2026 in JCO Global Oncology
Verified
Journal Article
Open access
DHDaniel Herchenhorn
Daniel Herchenhorn
HAHaonne Abboud
Haonne Abboud
VFVinicius Freire
Vinicius Freire
JTJuliana Tarouquella
Juliana Tarouquella
FMFernando Sabino Marques Monteiro
Fernando Sabino Marques Monteiro
NJNick James
Nick James
PURPOSE: The Brazilian Public Health System (BPHS) provides sole health coverage for approximately 77% of the population. Analyzing BPHS data enables nationwide assessment of epidemiology, treatment patterns, and costs for men with prostate cancer (PCa). METHODS: We conducted a retrospective, population-based cohort study using linked administrative data from the BPHS Database DATASUS for patients with PCa treated in the BPHS from January 1, 2008, to March 31, 2023. Variables include demographics, clinical features, stage, treatments, and health care utilization. The primary objective was to evaluate the impact of race on stage at diagnosis, treatment delivery, and treatment costs. RESULTS: A total of 670,205 patients with PCa were treated during the study period; 277,030 (41.4%) were White and 393,175 (58.6%) non-White. Mean age at diagnosis was 72.9 years (40-99). Approximately 56% were diagnosed with stage I-III disease (56.1% v 55.5%), and 21% with metastatic disease (19.7% v 21.2%), with non-White men more frequently presenting with advanced stage ( P < .001). White men more commonly received local therapy in stage I, whereas non-White men received local therapy more frequently in stage III ( P < .001). Among 125,759 men with stage IV disease who received systemic therapy, only 22,393 (17.8%) received docetaxel, while use of first-generation antiandrogens and estrogens remained high (25%). Total PCa-directed expenditures reached In$ 1.83 billion, with mean costs 16.2% higher for White patients than for non-White patients. CONCLUSION: In the BPHS, race was associated with more advanced stages at diagnosis and differences in treatment delivery. High rates of de novo metastatic disease, underuse of docetaxel, and persistent use of agents without survival benefit highlight urgent gaps in PCa care. These findings may guide PCa policy in Brazil and other low- and middle-income countries.

1 January 2026 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
DVDouglas Andreas Valverde
Douglas Andreas Valverde
Abel QuaresmaAbel Quaresma
Abel Quaresma
MVMaria Paz Gimenez Villamil
Maria Paz Gimenez Villamil
TMThyago Proenca Moraes
Thyago Proenca Moraes
PKPaulo Kotze
Paulo Kotze
Objective: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires advanced therapies, including infliximab, vedolizumab, and tofacitinib. Our aim is to understand the hospitalization rates and outcomes associated with these therapies in real-world scenarios, which is crucial for optimizing patient management and healthcare resource allocation. Methods: This nationwide retrospective observational study analyzed real-world data (RWD) from Brazil’s public healthcare system (SUS) between January 2021 and December 2023. Data on hospitalizations, length of stay, mortality, costs, and non-IBD-related hospital admissions were extracted and analyzed using the Techtrials TT Disease Explorer and TT RWE Generator, leveraging generative artificial intelligence (GenAI) for data integration and analysis. Results: A total of 1,313 patients required hospitalization, with 1,434 hospitalizations recorded. The hospitalization rate per 100 patients was highest for tofacitinib (262.5), followed by infliximab (212.88) and vedolizumab (191.67). Patients treated with infliximab had the shortest hospital stay (Median 3.0 days [0-68]) and lowest costs (Median 510.83 BRL [23.45 - 111,594.14]), whilst vedolizumab had the highest hospitalization costs. Surgical intervention rates were highest among tofacitinib users. Non-IBD-related hospitalizations suggested potential adverse drug events, including gastrointestinal disorders, infections, and anemia. Conclusion: This study represents the first AI-assisted RWE analysis of UC hospitalizations in Brazil. The findings highlight the varying hospitalization burdens across advanced therapies, with tofacitinib associated with higher hospitalization rates and infliximab linked to shorter hospital stays and lower costs. These insights can inform clinical decision-making and healthcare policy. Future studies should further explore AI’s role in optimizing RWE research and UC management.